Q3 EPS Estimate for Celldex Therapeutics Boosted by Analyst

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Stock analysts at HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for Celldex Therapeutics in a research note issued on Friday, August 7th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will post earnings per share of ($1.05) for the quarter, up from their prior forecast of ($1.12). HC Wainwright currently has a “Buy” rating and a $42.00 price target on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($4.36) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q4 2026 earnings at ($1.08) EPS, FY2026 earnings at ($4.23) EPS and FY2027 earnings at ($4.49) EPS.

Other equities research analysts also recently issued reports about the company. Wall Street Zen raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Friday, July 17th. Canaccord Genuity Group cut their price objective on shares of Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Guggenheim raised their target price on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, July 20th. Finally, Morgan Stanley lifted their target price on shares of Celldex Therapeutics from $40.00 to $46.00 and gave the company an “overweight” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.46.

Celldex Therapeutics Trading Up 3.0%

NASDAQ:CLDX opened at $42.97 on Tuesday. The firm has a market cap of $3.37 billion, a P/E ratio of -9.88 and a beta of 0.87. The stock’s 50 day simple moving average is $35.45 and its 200-day simple moving average is $31.70. Celldex Therapeutics has a 12-month low of $19.72 and a 12-month high of $43.21.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.12. The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.73 million.

Institutional Investors Weigh In On Celldex Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp purchased a new position in shares of Celldex Therapeutics in the 2nd quarter valued at about $8,342,000. Handelsbanken Fonder AB boosted its holdings in Celldex Therapeutics by 5.0% during the second quarter. Handelsbanken Fonder AB now owns 27,200 shares of the biopharmaceutical company’s stock worth $1,012,000 after buying an additional 1,300 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Celldex Therapeutics by 438.3% during the second quarter. Assenagon Asset Management S.A. now owns 788,696 shares of the biopharmaceutical company’s stock worth $29,347,000 after buying an additional 642,171 shares during the period. Apella Capital LLC grew its position in Celldex Therapeutics by 56.6% during the second quarter. Apella Capital LLC now owns 26,658 shares of the biopharmaceutical company’s stock worth $1,064,000 after buying an additional 9,634 shares during the period. Finally, Mirador Capital Partners LP increased its holdings in Celldex Therapeutics by 1.7% in the second quarter. Mirador Capital Partners LP now owns 181,054 shares of the biopharmaceutical company’s stock valued at $6,737,000 after buying an additional 3,001 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.